Imaging to predict who benefits from chemoimmunotherapy before lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This study uses CT scan images to help doctors predict which patients with resectable lung cancer will benefit most from receiving chemoimmunotherapy (a combination of chemotherapy and immunotherapy) before surgery. The goal is to personalize treatment planning and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed diagnosis of non-small cell lung cancer (NSCLC) that can be surgically removed
- Cancer stage IIIA or lower
- Planning to receive chemoimmunotherapy before surgery as part of standard care
- Good overall health and ability to care for yourself (ECOG score 0 or 1)
- Able to understand and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a treatment given before surgery for non-small cell lung cancer. Patients receive chemotherapy plus immunotherapy (chemo-immunotherapy) first, then have surgery to remove the tumor. The goal is to see how well this approach works.
This study looks at how well immunotherapy given before surgery works for non-small cell lung cancer. It aims to help doctors understand real-world outcomes for patients who receive this treatment.
This trial tests a combination of targeted radiation (SBRT), an immunotherapy drug (tislelizumab), and a targeted therapy (anlotinib) given before surgery for people with a certain type of lung cancer that has not spread too far. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial uses special tests (like looking at genes and proteins) to better understand which patients with non-small cell lung cancer (NSCLC) will benefit most from immunotherapy given before surgery. It aims to create a tool to predict treatment success.
This trial studies a comprehensive treatment approach for lung cancer that combines immunotherapy given before surgery with standard surgery. It aims to understand how well this approach works by analyzing your medical data and samples.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
Hear when a new Neoadjuvant Chemoimmunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.